SANOFI-AVENTIS (EPA:SAN) New pivotal data at EHA 2021 reinforces sutimlimab as a first-in-class investigational C1s inhibitor with the potential to be the first approved treatment for hemolysis in people with CAD, a serious and chronic autoimmune hemolytic anemia
Transparency directive : regulatory news
11/06/2021 09:00
SANOFI-AVENTIS's latest news
17/04/2024 07:00
12/04/2024 20:05
22/03/2024 07:30
15/03/2024 20:04
24/02/2024 15:51
23/02/2024 18:45
23/02/2024 07:00
22/02/2024 19:02
20/02/2024 23:40
15/02/2024 14:00
Other stories
26/04/2024 16:40
26/04/2024 22:53
26/04/2024 19:55
26/04/2024 19:00
26/04/2024 20:33
26/04/2024 14:26
26/04/2024 20:13
26/04/2024 23:33
26/04/2024 21:00
26/04/2024 18:59
26/04/2024 21:59
26/04/2024 18:22
26/04/2024 21:21
26/04/2024 17:57
26/04/2024 16:15
26/04/2024 16:55
26/04/2024 14:07
26/04/2024 16:56
26/04/2024 17:19
26/04/2024 20:31
26/04/2024 12:30
26/04/2024 18:00
26/04/2024 22:01
26/04/2024 21:03
26/04/2024 22:40
26/04/2024 04:24
26/04/2024 18:58
26/04/2024 09:00
26/04/2024 22:57
26/04/2024 14:57
25/04/2024 19:30
26/04/2024 10:24
26/04/2024 18:00
26/04/2024 17:35
26/04/2024 13:30
26/04/2024 22:49
26/04/2024 21:58
26/04/2024 03:31